Anti-idiotype immunomodulation of experimental anti-phospholipid syndrome via effect on Th1/Th2 expression

I. Krause, M. Blank, Y. Levi, T. Koike, V. Barak, Y. Shoenfeld

Research output: Contribution to journalArticlepeer-review


Mice with experimental anti-phospholipid syndrome (APS), induced by active immunization with a human anti-cardiolipin MoAb (H-3), were treated with mouse anti-idiotypic MoAb (anti-H3, named S2.9) and with an irrelevant anti-idiotype. The immunized mice produced high titres of mouse anticardiolipin antibodies along with clinical manifestations of experimental APS: prolonged activated partial thromboplastin time (aPTT), thrombocytopenia and high rate of fetal loss. Treatment with the specific anti-Id (S2.9) as a whole molecule or F(ab)2 fraction, resulted in a decrease in serum levels of the anti-cardiolipin antibodies, rise in platelet count, shortened aPTT and reduced rate of fetal loss. The anti-Id effect was associated with a rise in the number of IL-2 and interferon-gamma (IFN-γ)-secreting cells (Th1) and reduction in IL-4- and IL-6-secreting cells (Th2). The beneficial effect of the anti-Id treatment in mice with experimental APS induced by active immunization with an idiotype further supports the idiotypic aetiology of experimental APS and points to the role of Th1 cytokines in suppression of its manifestations.

Original languageEnglish
Pages (from-to)190-197
Number of pages8
JournalClinical and Experimental Immunology
Issue number1
StatePublished - 1999


  • Anti- cardiolipin antibodies
  • Anti-idiotype
  • Anti-phospholipid syndrome
  • Th1 cells
  • Th2 cells


Dive into the research topics of 'Anti-idiotype immunomodulation of experimental anti-phospholipid syndrome via effect on Th1/Th2 expression'. Together they form a unique fingerprint.

Cite this